Ascendis Pharma A/S (ASND)
135.13
-2.32
(-1.69%)
USD |
NASDAQ |
May 31, 16:00
135.13
0.00 (0.00%)
After-Hours: 20:00
Ascendis Pharma Cash from Operations (Quarterly): -110.34M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -110.34M |
| December 31, 2023 | -43.35M |
| September 30, 2023 | -135.30M |
| June 30, 2023 | -169.39M |
| March 31, 2023 | -157.93M |
| December 31, 2022 | -166.14M |
| September 30, 2022 | -84.81M |
| June 30, 2022 | -125.05M |
| March 31, 2022 | -146.76M |
| December 31, 2021 | -147.11M |
| September 30, 2021 | -109.84M |
| June 30, 2021 | -138.85M |
| March 31, 2021 | -98.35M |
| December 31, 2020 | -98.20M |
| September 30, 2020 | -76.01M |
| June 30, 2020 | -62.20M |
| March 31, 2020 | -73.70M |
| December 31, 2019 | -56.08M |
| September 30, 2019 | -65.89M |
| June 30, 2019 | -5.858M |
| March 31, 2019 | -69.13M |
| Date | Value |
|---|---|
| December 31, 2018 | -43.85M |
| September 30, 2018 | -52.16M |
| June 30, 2018 | -22.75M |
| March 31, 2018 | -45.13M |
| December 31, 2017 | -24.30M |
| September 30, 2017 | -33.71M |
| June 30, 2017 | -27.06M |
| March 31, 2017 | -22.64M |
| December 31, 2016 | -18.03M |
| September 30, 2016 | -17.31M |
| June 30, 2016 | -14.84M |
| March 31, 2016 | -16.42M |
| December 31, 2015 | -11.03M |
| September 30, 2015 | -13.94M |
| June 30, 2015 | -15.22M |
| March 31, 2015 | -8.050M |
| December 31, 2014 | -10.23M |
| September 30, 2014 | -4.142M |
| June 30, 2014 | -6.638M |
| March 31, 2014 | -3.468M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-169.39M
Minimum
Jun 2023
-5.858M
Maximum
Jun 2019
-103.56M
Average
-104.10M
Median
Cash from Operations (Quarterly) Benchmarks
| Evaxion Biotech AS | -- |
| Biodexa Pharmaceuticals Plc | -- |
| Trinity Biotech PLC | -2.819M |
| NuCana PLC | -7.462M |
| TC BioPharm (Holdings) PLC | -3.055M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 7.772M |
| Cash from Financing (Quarterly) | 20.01M |
| Free Cash Flow | -460.07M |
| Free Cash Flow Per Share (Quarterly) | -1.944 |
| Free Cash Flow to Equity (Quarterly) | -230.06M |
| Free Cash Flow to Firm (Quarterly) | -29.07M |
| Free Cash Flow Yield | -6.03% |